Table 1.

Karyotypes and DNA indexes of patients with hypodiploidy with 30 to 39 chromosomes and with near-triploidy

Patient no.
Modal no.*
DNA index (% of leukemic cells in G0/G1)
Karyotype
1   32   ND   32<n>,X,+Y,+1,+6,+8,+10,+11,+19,+21,+22[7]°/46,XY[5]  
2   34   0.72 (43)/1.43 (39)   33-35<n>,X,+X,+1,+5,+6,+8,+10,+13,+14,+18,+19,+21[cp5]/64-68,idemx2[cp6]/46,XX[14]  
3   34   ND   34<n>,X,+1,+6,+8,+10,+11,+12,+14,+16,+18,+19,+21[6]/46,XX[6]  
4   34   0.78 (22.4)/1.89 (3.8)   34<n>,X,+1,+5,+6,+7,+9,+10,+11,+18,+19,+20,+21[2]/69-74,idemx2,-7,+13,+14,-19,+22[cp8]/46,XY[11]  
5   35   0.78 (56)/1.55 (26)   35<n>,X,del(1)(q32q43),+1,del(5)(q24q34),+5,+6,+8,+9,+10,+11,+14,+18,+19,+21,+22[14]/70,idemx2[2]/46,XY[4]  
6   37   ND   37<n>,X+Y,+1,+4,+del(5)q23q35),+6,+8,+10,+11,+12,+14,+18,+19,+21,+22[5]/74,idemx2[3]  
7   36   0.82 (2.3)† 1.58 (2.5) Relapse: 1.43 (93)   36<n>,X,+Y,+1,+2,+4,+5,+6,+11,+16,+18,+19,+20,+21,+mar[7]/46,XY[12] Relapse: 62-64<3n>,XXY,add(3)(p21),-3,-7,-8,-13,-14,+16,-17,-28,+mar[21]  
8   37   ND   37<n>,X,+1,+3,+5,+7,+8,+9,+10,+11,+14,+15,+16,+19,+20,+22,inc[14]/46,XY[21]  
9   38   0.87 (44.7)/1.67 (29.2)   38<n>,X,+1,+2,+4,+5,+6,+8,+9,+10,+11,+12,+13,+14,+20,+21,+22[8]/76<3n>,idemx2[9]/46,XX[1]  
10   39   0.82 (53.1)   39<n>,X,+1,+4,+5,+6,del(6)(q23),+7,+8,+9,+10,+11,+14,+17,+18,+19,+20,+2mar[11]/72-75,idemx2[2]/46,XX[18]  
11   39   ND   39<n>,X,+Y,+1,+2,+5,+6,+8,+9,+10,+11,+12,+13,+14,+19,+20,+21,+22[6]/46,XY[14]  
12   64   ND   64<3n>,XX,-2,-3,+5,i(7)(q10),+9,-12,del(12)(p11),-13,-14,-15,-17,+18,-19,+mar,inc[3]/46,XX[5]  
13   70   ND   69-71<3n>,XY,+1,-3,-4,+6,-7,-13,-15,+22,+3-5mar[cp12]/46,XY[3]  
14   68   ND   68-70<3n>,XXX,+1,-3,add(4)(q10),-7,+8,+11,+12,-13,-15,-16,-17,+18,-19,+21[cp11]/46,XX[5]  
15   65   1.41 (8)   63-66<3n>,XXY,+1,-2,-3,-4,+5,-7,+8,-10,-12,-13,+14,-15,-16,-17,+18,-20,+21,+22[cp4]/46,XY[7]  
16   65   1.39 (7)   64-66<3n>,XXX,+1,-3,-4,-5,+6,-7,-9,-10,+11,-13,+14,-15,-16,-17,+19,-20,+21,+22[cp20]  
17   67   0.72 (12)/1.44 (57)   66-67,<3n>,XX,+1,-3,-5,-7,-9,+11,-14,-15,-16,-17,+19,+21,+22,+2mar[cp11]/46,XX[3]  
18   70   0.8 (12)/1.56 (10)   70<3n>,XXY,+Y,+1,-2,-3,+4,+5,+6,-7,+8,-9,+10,+11,-12,-13,-14,-15,-16,-17,+18,+19,-20,+21,+22[4]/46,XY[11]  
19   68   0.8 (25)/1.53 (52)   68<3n>,XXY,+1,-3,-4,+6,-7,-15,+22[12]/46,XY[3]  
20   73   0.82 (41)/1.59 (10)  73<3n>,XXY,+Y,+1,-3,-4,add(5)(q13),+6,-9,+11,+12,+14,-15,-17,+18,+21,+22,inc[11)  
21   69   ND   69-73<3n>,XXY,-3,-4,-5,+6,-7,+8,-9,+10,+11,+12,-13,+14,-15,-16,-17,+21,+22,+mar[cp7]/46,XY[12]  
22   69   0.88 (18)/1.53 (25)   66-70,<3n>XXX,add(2)(q37),-3,-4,-7,del(7)(q21q35),-9,-14,-15,-17,+19,+21,+22,+1-5mar[cp15]/46,XX[7]  
23   74   0.78 (23)/1.49 (76)   68-74<3n>,XXY,+Y,-3,-4,-5,+6,-7,+8,-9,+11,-15,+18,+19,+21×2,+22×2,+mar[cp10]  
24
 		 74
 		 0.82 (2)/1.56 (21)
 		 72-74<3n>,XXY,+Y,+1,-2,-3,-4,+6×2,-9,+10,+11,-12,+14,-15,-17,+18×2,+19×2,-20,+21,+22,+mar[cp20]
 
Patient no.
Modal no.*
DNA index (% of leukemic cells in G0/G1)
Karyotype
1   32   ND   32<n>,X,+Y,+1,+6,+8,+10,+11,+19,+21,+22[7]°/46,XY[5]  
2   34   0.72 (43)/1.43 (39)   33-35<n>,X,+X,+1,+5,+6,+8,+10,+13,+14,+18,+19,+21[cp5]/64-68,idemx2[cp6]/46,XX[14]  
3   34   ND   34<n>,X,+1,+6,+8,+10,+11,+12,+14,+16,+18,+19,+21[6]/46,XX[6]  
4   34   0.78 (22.4)/1.89 (3.8)   34<n>,X,+1,+5,+6,+7,+9,+10,+11,+18,+19,+20,+21[2]/69-74,idemx2,-7,+13,+14,-19,+22[cp8]/46,XY[11]  
5   35   0.78 (56)/1.55 (26)   35<n>,X,del(1)(q32q43),+1,del(5)(q24q34),+5,+6,+8,+9,+10,+11,+14,+18,+19,+21,+22[14]/70,idemx2[2]/46,XY[4]  
6   37   ND   37<n>,X+Y,+1,+4,+del(5)q23q35),+6,+8,+10,+11,+12,+14,+18,+19,+21,+22[5]/74,idemx2[3]  
7   36   0.82 (2.3)† 1.58 (2.5) Relapse: 1.43 (93)   36<n>,X,+Y,+1,+2,+4,+5,+6,+11,+16,+18,+19,+20,+21,+mar[7]/46,XY[12] Relapse: 62-64<3n>,XXY,add(3)(p21),-3,-7,-8,-13,-14,+16,-17,-28,+mar[21]  
8   37   ND   37<n>,X,+1,+3,+5,+7,+8,+9,+10,+11,+14,+15,+16,+19,+20,+22,inc[14]/46,XY[21]  
9   38   0.87 (44.7)/1.67 (29.2)   38<n>,X,+1,+2,+4,+5,+6,+8,+9,+10,+11,+12,+13,+14,+20,+21,+22[8]/76<3n>,idemx2[9]/46,XX[1]  
10   39   0.82 (53.1)   39<n>,X,+1,+4,+5,+6,del(6)(q23),+7,+8,+9,+10,+11,+14,+17,+18,+19,+20,+2mar[11]/72-75,idemx2[2]/46,XX[18]  
11   39   ND   39<n>,X,+Y,+1,+2,+5,+6,+8,+9,+10,+11,+12,+13,+14,+19,+20,+21,+22[6]/46,XY[14]  
12   64   ND   64<3n>,XX,-2,-3,+5,i(7)(q10),+9,-12,del(12)(p11),-13,-14,-15,-17,+18,-19,+mar,inc[3]/46,XX[5]  
13   70   ND   69-71<3n>,XY,+1,-3,-4,+6,-7,-13,-15,+22,+3-5mar[cp12]/46,XY[3]  
14   68   ND   68-70<3n>,XXX,+1,-3,add(4)(q10),-7,+8,+11,+12,-13,-15,-16,-17,+18,-19,+21[cp11]/46,XX[5]  
15   65   1.41 (8)   63-66<3n>,XXY,+1,-2,-3,-4,+5,-7,+8,-10,-12,-13,+14,-15,-16,-17,+18,-20,+21,+22[cp4]/46,XY[7]  
16   65   1.39 (7)   64-66<3n>,XXX,+1,-3,-4,-5,+6,-7,-9,-10,+11,-13,+14,-15,-16,-17,+19,-20,+21,+22[cp20]  
17   67   0.72 (12)/1.44 (57)   66-67,<3n>,XX,+1,-3,-5,-7,-9,+11,-14,-15,-16,-17,+19,+21,+22,+2mar[cp11]/46,XX[3]  
18   70   0.8 (12)/1.56 (10)   70<3n>,XXY,+Y,+1,-2,-3,+4,+5,+6,-7,+8,-9,+10,+11,-12,-13,-14,-15,-16,-17,+18,+19,-20,+21,+22[4]/46,XY[11]  
19   68   0.8 (25)/1.53 (52)   68<3n>,XXY,+1,-3,-4,+6,-7,-15,+22[12]/46,XY[3]  
20   73   0.82 (41)/1.59 (10)  73<3n>,XXY,+Y,+1,-3,-4,add(5)(q13),+6,-9,+11,+12,+14,-15,-17,+18,+21,+22,inc[11)  
21   69   ND   69-73<3n>,XXY,-3,-4,-5,+6,-7,+8,-9,+10,+11,+12,-13,+14,-15,-16,-17,+21,+22,+mar[cp7]/46,XY[12]  
22   69   0.88 (18)/1.53 (25)   66-70,<3n>XXX,add(2)(q37),-3,-4,-7,del(7)(q21q35),-9,-14,-15,-17,+19,+21,+22,+1-5mar[cp15]/46,XX[7]  
23   74   0.78 (23)/1.49 (76)   68-74<3n>,XXY,+Y,-3,-4,-5,+6,-7,+8,-9,+11,-15,+18,+19,+21×2,+22×2,+mar[cp10]  
24
 		 74
 		 0.82 (2)/1.56 (21)
 		 72-74<3n>,XXY,+Y,+1,-2,-3,-4,+6×2,-9,+10,+11,-12,+14,-15,-17,+18×2,+19×2,-20,+21,+22,+mar[cp20]
 

ND indicates not done.

*

Model number is the most common chromosome number in a tumor cell population.20 

†

At diagnosis, as analyzed by flow cytometry, the hypodiploid peak was slightly higher than the sensitivity threshold, whereas the near-triploid peak was clearly detected.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal